Rontilona

Rontilona

  • Active Ingredient: Fluticasone
  • 50mcg
Buy Now

What is Rontilona?

The active ingredient of Rontilona brand is fluticasone. Fluticasone propionate has a molecular weight of 500.6. It is a white to off-white powder and is insoluble in water. Each gram of Fluticasone Propionate Cream, USP 0.05% contains Fluticasone propionate 0.5 mg in a base of propylene glycol, mineral oil, cetostearyl alcohol, Ceteth-20, isopropyl myristate, dibasic sodium phosphate, citric acid, purified water, and methylparaben as preservative.

Used for

Rontilona is used to treat diseases such as: Asthma, Maintenance, Bronchopulmonary Dysplasia, Eosinophilic Esophagitis.

Side Effect

Possible side effects of Rontilona include: trouble swallowing; growth reduction in children or adolescents; bone fractures; loss of voice; pain in the back, ribs, arms or legs; Cough; muscle wasting.

How to Buy Rontilona online?

To buy Rontilona online - simply click on the "Buy Now" button in the top and follow on to our store. Payment and Order takes a few minutes, and all measures are evident. We don't take a medical prescription plus also we have many procedures of payment. With each detail of fast delivery and confidentiality, then you may read on the applicable pages on the hyperlinks in the navigation menu.

Related Medications

Ristad

Ristad 4mg, 2mg, 1mg

risperidone

More info

Dopezil

Dopezil 10mg, 5mg

donepezil

More info

Crialix

Crialix 10mg, 5mg

donepezil

More info

Rispex

Rispex 4mg, 2mg, 1mg

risperidone

More info

COMMON BRAND(S): Xhance

GENERIC NAME(S): Rontilona Propionate

Rontilona is used to treat certain growths in the nose (nasal polyps). It belongs to a class of drugs known as corticosteroids. Rontilona works by reducing swelling (inflammation) in the nasal passages. This can help decrease symptoms such as stuffy nose.

Pediatric Use

The safety and effectiveness of Rontilona propionate nasal spray in children aged 4 years and older have been established . Six hundred fifty (650) subjects aged 4 to 11 years and 440 subjects aged 12 to 17 years were studied in US clinical trials with Rontilona propionate nasal spray. The safety and effectiveness of Rontilona propionate nasal spray in children younger than 4 years have not been established.

Effects on Growth: Controlled clinical trials have shown that intranasal corticosteroids may cause a reduction in growth velocity when administered to pediatric patients. This effect was observed in the absence of laboratory evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The long-term effects of this reduction in growth velocity associated with intranasal corticosteroids, including the impact on final adult height, are unknown. The potential for “catch-up” growth following discontinuation of treatment with intranasal corticosteroids has not been adequately studied. The growth of pediatric patients receiving intranasal corticosteroids, including Rontilona propionate nasal spray, should be monitored routinely (e.g., via stadiometry). The potential growth effects of prolonged treatment should be weighed against the clinical benefits obtained and the risks associated with alternative therapies. To minimize the systemic effects of intranasal corticosteroids, including Rontilona propionate nasal spray, each patient’s dosage should be titrated to the lowest dosage that effectively controls his/her symptoms.

A 1-year placebo-controlled trial was conducted in 150 pediatric subjects (aged 3 to 9 years) to assess the effect of Rontilona propionate nasal spray (single daily dose of 200 mcg) on growth velocity. From the primary population receiving Rontilona propionate nasal spray (n=56) and placebo (n=52), the point estimate for growth velocity with Rontilona propionate nasal spray was 0.14 cm/year lower than placebo (95% CI:-0.54, 0.27 cm/year). Thus, no statistically significant effect on growth was noted compared with placebo. No evidence of clinically relevant changes in HPA axis function or bone mineral density was observed as assessed by 12-hour urinary cortisol excretion and dual-energy x-ray absorptiometry, respectively.

The potential for Rontilona propionate nasal spray to cause growth suppression in susceptible patients or when given at higher than recommended dosages cannot be ruled out.

Answer

Both Flonase and Veramyst do contain the same corticosteroid, Rontilona. And they're both made by the same manufacturer.

The difference between the 2 preparations is that in Flonase, the Rontilona is bonded with propionate and in Veramyst, it's with furoate, as you said. Those are not meds in and of themselves, just chemicals that help the Rontilona do its job.

As far as I can tell, there's no significant difference between the 2 medicines, though studies proving Veramyst's efficacy with eye allergy symptoms enables it to market that. In reality, though, anecdotal evidence pretty much shows that most nasal steroids help with eye symptoms too.

Here's some more information on Flonase and Veramyst.

Mechanism of Action

Rontilona propionate is a synthetic, trifluorinated corticostero >in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is 18 times that of dexamethasone, almost twice that of beclomethasone-17-monopropionate (BMP), the active metabolite of beclomethasone dipropionate, and over 3 times that of budesonide. Data from the McKenzie vasoconstrictor assay in man are consistent with these results. The clinical significance of these findings is unknown.

The precise mechanism through which Rontilona propionate affects rhinitis symptoms is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. In 7 trials in adults, Rontilona propionate nasal spray has decreased nasal mucosal eosinophils in 66% of patients (35% for placebo) and basophils in 39% of patients (28% for placebo). The direct relationship of these findings to long-term symptom relief is not known.

Serious side effects

Call your doctor right away if you have serious side effects. Call 911 if your symptoms feel life-threatening or if you think you’re having a medical emergency. Serious side effects and their symptoms can include the following:

  • Pneumonia, especially for people with COPD. Symptoms can include:
    • increase in mucus production
    • change in mucus color
    • fever
    • chills
    • increased cough
    • increased breathing problems
  • runny or stuffy nose
  • sore throat
  • drainage from your ear
  • ear pain
  • fever
  • fatigue
  • tiredness
  • loss of energy
  • weakness
  • nausea and vomiting
  • low blood pressure, which may make you feel dizzy or faint
  • Sudden trouble breathing right after you inhale your medication
  • skin rash
  • hives
  • swelling of your face, mouth, and tongue
  • breathing problems
  • high blood pressure, which can cause headache
  • fast or irregular heart rate
  • chest pain
  • tremors
  • nervousness
  • a bone break that happens more easily than expected
  • height loss or stooped posture if your spine is affected
  • Slowed growth in children. Your child’s doctor should check their growth often during treatment with this drug.
  • eye pain
  • blurred vision
  • seeing bright circles (halos) around lights
  • loss of night vision
  • light sensitivity
  • yellow tint to your vision
  • red, spotty rash
  • muscle or joint pain
  • chest pain
  • numbness or altered sensations due to nerve involvement
  • rapidly worsening shortness of breath or wheezing
  • muscle cramps
  • muscle twitches
  • increased urination
  • increased thirst
  • irregular heart beat
  • increased urination
  • increased thirst
  • fatigue
  • Disclaimer: Our goal is to provide you with the most relevant and current information. However, because drugs affect each person differently, we cannot guarantee that this information includes all possible side effects. This information is not a substitute for medical advice. Always discuss possible side effects with a healthcare provider who knows your medical history.

    Rontilona/salmeterol inhalation powder can interact with other medications, vitamins, or herbs you may be taking. An interaction is when a substance changes the way a drug works. This can be harmful or prevent the drug from working well.

    To help avoid interactions, your doctor should manage all of your medications carefully. Be sure to tell your doctor about all medications, vitamins, or herbs you’re taking. To find out how this drug might interact with something else you’re taking, talk to your doctor or pharmacist.

    Examples of drugs that can cause interactions with Rontilona/salmeterol are listed below.

    In clinical trials with Rontilona propionate administered intranasally, the development of localized infections of the nose and pharynx with Candida albicans has occurred. When such an infection develops, it may require treatment with appropriate local therapy and discontinuation of FLONASE Nasal Spray. Patients using FLONASE Nasal Spray over several months or longer should be examined periodically for evidence of Candida infection or other signs of adverse effects on the nasal mucosa.

    Adults

    The recommended starting dosage in adults is 2 sprays (50 mcg of Rontilona propionate each) in each nostril once daily (total daily dose, 200 mcg). The same total daily dose, 1 spray in each nostril administered twice daily (e.g., 8 a.m. and 8 p.m.) is also effective. After the first few days, patients may be able to reduce their dose to 1 spray in each nostril once daily for maintenance therapy.

    Maximum total daily doses should not exceed 2 sprays in each nostril (total dose, 200 mcg/day). There is no evidence that exceeding the recommended dose is more effective.

    Getting the most from your treatment

    • Rontilona is a preventer inhaler which needs to be used regularly in order to have an effect. It takes a few days for the steroid in the inhaler to build up its effect.
    • Rontilona inhalers will not give you immediate relief if you are having an asthma attack - you will need to use a reliever inhaler to ease the symptoms of an attack.
    • If after using the inhaler for the first time your breathing becomes worse or you suddenly start to wheeze, let your doctor know straightaway. Your doctor will want to change the type of inhaler to one more suited to you.
    • It is helpful to remember the colour of your inhaler and the brand name. This might be important if you need to see a doctor who does not have your medical records (such as if you are on holiday or if it is outside the normal opening hours of your GP surgery).
    • Keep your regular appointments with your doctor or asthma clinic. This is so your doctor can review your treatment. If at any time you find that your asthma symptoms are getting worse or that you need to use a reliever inhaler more regularly, contact your doctor or nurse for advice straightaway.
    • If you are using a high dose of Rontilona, you will also be given a steroid card. You are advised to carry the card with you at all times in case you need any treatment by a doctor who does not have your medical records available.
    • Continue to use your Rontilona inhaler regularly. Do not stop using it abruptly, as this can make you feel unwell and cause your symptoms to return suddenly.
    • Do not smoke. Smoking can cause severe irritation and damage to your lungs. It will make your condition worse and will reduce the beneficial effects of your inhalers.
    • If you have diabetes, tell your doctor if you notice any change in your blood glucose tests, as Rontilona may affect the levels of sugar in your blood.

    OVERDOSAGE

    Topically applied Rontilona Propionate Cream can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).

    Postmarketing Experience

    In addition to adverse events reported from clinical trials, the following adverse events have been identified during postapproval use of intranasal Rontilona propionate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to Rontilona propionate or a combination of these factors.

    General Disorders and Administration Site Conditions : Hypersensitivity reactions, including angioedema, skin rash, edema of the face and tongue, pruritus, urticaria, bronchospasm, wheezing, dyspnea, and anaphylaxis/anaphylactoid reactions, which in rare instances were severe.

    Ear and Labyrinth Disorders : Alteration or loss of sense of taste and/or smell and, rarely, nasal septal perforation, nasal ulcer, sore throat, throat irritation and dryness, cough, hoarseness, and voice changes.

    Eye Disorders : Dryness and irritation, conjunctivitis, blurred vision, glaucoma, increased intraocular pressure, and cataracts.

    Cases of growth suppression have been reported for intranasal corticostero > .

    Carcinogenesis, Mutagenesis, Impairment Of Fertility

    Rontilona propionate demonstrated no tumorigenic potential in mice at oral doses up to 1,000 mcg/kg (approximately 20 times the MRHDID in adults and approximately 10 times the MRHDID in children on a mcg/m² basis) for 78 weeks or in rats at inhalation doses up to 57 mcg/kg (approximately 2 times the MRHDID in adults and approximately equivalent to the MRHDID in children on a mcg/m² basis) for 104 weeks.

    Rontilona propionate did not induce gene mutation in prokaryotic or eukaryotic cells in vitro. No significant clastogenic effect was seen in cultured human peripheral lymphocytes in vitro or in the mouse micronucleus test.

    No evidence of impairment of fertility was observed in male and female rats at subcutaneous doses up to 50 mcg/kg (approximately 2 times the MRHDID in adults on a mcg/m² basis). Prostate weight was significantly reduced at a subcutaneous dose of 50 mcg/kg.

    Rontilona and Lactation

    Tell your doctor if you are breastfeeding or plan to breastfeed. It is not known if Rontilona is excreted in human breast milk or if it will harm your nursing baby.

    Adverse Reactions

    In controlled clinical trials of twice-daily administration, the total incidence of adverse reactions associated with the use of Rontilona Propionate Cream was approximately 4%. These adverse reactions were usually mild; self-limiting; and consisted primarily of pruritus, dryness, numbness of fingers, and burning. These events occurred in 2.9%, 1.2%, 1.0%, and 0.6% of patients, respectively.

    Two clinical studies compared once- to twice-daily administration of Rontilona Propionate Cream for the treatment of moderate to severe eczema. The local drug-related adverse events for the 491 patients enrolled in both studies are shown in Table 1. In the study enrolling both adult and pediatric patients, the incidence of local adverse events in the 119 pediatric patients ages 1 to 12 years was comparable to the 140 patients ages 13 to 62 years.

    Fifty-one pediatric patients ages 3 months to 5 years, with moderate to severe eczema, were enrolled in an open-label HPA axis safety study. Rontilona Propionate Cream was applied twice daily for 3 to 4 weeks over an arithmetic mean body surface area of 64% (range, 35% to 95%). The mean morning cortisol levels with standard deviations before treatment (prestimulation mean value = 13.76 ± 6.94 mcg/dL, poststimulation mean value = 30.53 ± 7.23 mcg/dL) and at end treatment (prestimulation mean value = 12.32 ± 6.92 mcg/dL, poststimulation mean value = 28.84 ± 7.16 mcg/dL) showed little change. In 2 of 43 (4.7%) patients with end-treatment results, peak cortisol levels following cosyntropin stimulation testing were 18 µg/dL, indicating adrenal suppression. Follow-up testing after treatment discontinuation, available for 1 of the 2 subjects, demonstrated a normally responsive HPA axis. Local drug-related adverse events were transient burning, resolving the same day it was reported; transient urticaria, resolving the same day it was reported; erythematous rash; dusky erythema, resolving within 1 month after cessation of Rontilona Propionate Cream; and telangiectasia, resolving within 3 months after stopping Rontilona Propionate Cream.

    Read more about can you buy Osteobon for treat Osteoporosis

    How should this medicine be used?

    Rontilona comes as an aerosol to inhale by mouth using an inhaler and as a powder to inhale by mouth using an inhaler. Rontilona aerosol oral inhalation (Flovent HFA) is usually inhaled twice daily. Rontilona powder for oral inhalation is usually inhaled once daily (Armonair, Arnuity Ellipta) or twice daily (Armonair Respiclick, Flovent Diskus). Try to use Rontilona at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Use Rontilona exactly as directed. Do not use more or less of it or use it more often than prescribed by your doctor.

    Talk to your doctor about how you should use your other oral and inhaled medications for asthma during your treatment with Rontilona inhalation. If you are using any other inhaled medications, ask your doctor if you should inhale these medications a certain amount of time before and after you inhale Rontilona inhalation. If you were taking an oral steroid such as dexamethasone, methylprednisolone (Medrol), or prednisone (Rayos), your doctor may want to gradually decrease your steroid dose starting at least 1 week after you begin to use Rontilona.

    Rontilona helps to prevent asthma attacks (sudden episodes of shortness of breath, wheezing, and coughing) but will not stop an asthma attack that has already started. Do not use Rontilona during an asthma attack. Your doctor will prescribe a short-acting inhaler to use during asthma attacks.

    Your doctor will probably start you on an average dose of Rontilona. Your doctor may decrease your dose when your symptoms are controlled or increase it if your symptoms have not improved after at least 2 weeks.

    Rontilona controls asthma but does not cure it. Your symptoms may improve 24 hours after you begin using Rontilona, but it may take 2 weeks or longer before you feel the full benefit of the medication. Continue to use Rontilona even if you feel well. Do not stop using Rontilona without talking to your doctor.

    If your child will be using the inhaler, be sure that they know how to use it. Watch your child each time they use the inhaler to be sure that they are using it correctly.

    Tell your doctor if your asthma worsens during your treatment. Call your doctor if you have an asthma attack that does not stop when you use your fast-acting asthma medication, or if you need to use more of your fast-acting medication than usual.

    The inhaler that comes with Rontilona aerosol is designed for use only with a canister of Rontilona. Never use it to inhale any other medication, and never use any other inhaler to inhale Rontilona.

    Each product is designed to provide 30, 60, or120 inhalations, depending on the type of inhaler. After the labeled number of inhalations has been used, later inhalations may not contain the correct amount of medication. You should keep track of the number of inhalations you have used. You can divide the number of inhalations in your inhaler by the number of inhalations you use each day to find out how many days your inhaler will last. Dispose of the canister after you have used the labeled number of inhalations even if it still contains some liquid and continues to release a spray when it is pressed. Do not float the canister in water to see if it still contains medication.

    Do not use your Rontilona aerosol inhaler while you are near an open flame or a heat source. The inhaler may explode if it is exposed to very high temperatures.

    Before you use Rontilona the first time, read the written instructions that come with it. Look at the diagrams carefully and be sure that you recognize all the parts of the inhaler. Ask your doctor, pharmacist, or respiratory therapist to show you how to use it. Practice using the inhaler while they watch you.

    Hepatic Impairment

    Formal pharmacokinetic trials using FLONASE Nasal Spray have not been conducted in subjects with hepatic impairment. Since Rontilona propionate is predominantly cleared by hepatic metabolism, impairment of liver function may lead to accumulation of Rontilona propionate in plasma. Therefore, patients with hepatic disease should be closely monitored.

    Flonase Warnings

    You may not experience the full benefits of Flonase for two weeks or more after starting treatment.

    Rontilona may also make it harder for your body to fight off infections. While taking the drug, your body may be less able to manage the stress of surgery, illness, severe asthma attack, or injury.

    While taking Rontilona, you should avoid people who are sick, especially those with chickenpox or measles. If you get one of these infections or if you develop related symptoms, call your doctor right away.

    Flonase could increase your risk for developing osteoporosis, a condition that causes the bones to become thin and break easily. If you're already at greater risk for osteoporosis, it's important to have your bone density assessed both before and during treatment.

    Research shows that in rare cases, people taking Rontilona for a long period of time may develop glaucoma or cataracts.

    Before taking Rontilona, be sure to let your doctor know if you've ever had any of the following:

    • Glaucoma
    • Cataracts
    • Other illnesses
    • Recurring infections (such as herpes)
    • Allergies
    • Tuberculosis
    • Liver disease

    Also let your doctor know if you've never had chickenpox or measles and never got a vaccination against those diseases.

    Although Rontilona can help prevent asthma attacks, it will not stop an attack that has already begun. Don't use Rontilona during an asthma attack.

    You should also let your doctor know if you have any type of surgery planned, including dental procedures.

    How Supplied/Storage and Handling

    Rontilona Propionate Nasal Spray USP, 50 mcg is supplied in an amber glass bottle fitted with a white metering atomizing pump, white nasal adapter fitted with a clear plastic dust cap, and a green safety clip, in a box of one (NDC 0054-3270-99) with FDA-approved Patient Labeling (see Patient Instructions for Use for proper actuation of the device). Each bottle contains a net fill weight of 16 g and will provide 120 actuations. Each actuation delivers 50 mcg of Rontilona propionate in 100 mg of formulation through the nasal adapter. The correct amount of medication in each spray cannot be assured after 120 sprays even though the bottle is not completely empty. The bottle should be discarded when the labeled number of actuations has been used.

    Store between 4° and 30°C (39° and 86°F).

    Flonase and Pregnancy

    Be sure your doctor knows if you are pregnant, may become pregnant, or are breastfeeding.

    There's not enough evidence to know whether Flonase is safe for pregnant women or breastfeeding infants.

    Evidence also is lacking on whether nasal or inhaled Rontilona is safe or effective for treating kids younger than 4.

    Children older than 4 who take the drug may grow more slowly, and it's unclear whether their final adult height will be shorter than it would have been had they not taken Rontilona.

    Children 3 months and older can use topical Rontilona with caution. There's no evidence of safety or effectiveness of the drug when used on young children for longer than 4 weeks.


    © Copyright 2017-2020 - rootsdentclinic.com - We Care About You!

    Sitemap